Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Fox

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|April 2, 2020
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survivalNicolás Martinez-Calle, Edward Poynton, Alia Alchawaf, et al.
Blood Advances|November 15, 2023
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experienceRohan Shotton, Rachel Broadbent, Alia Alchawaf, et al.
Haematologica|December 1, 2020
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trialAndrew R Pettitt, Richard Jackson, Silvia Cicconi, et al.
Neuro-Oncology|February 9, 2021
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)Ramon F Barajas, Letterio S Politi, Nicoletta Anzalone, et al.
Blood Advances|August 31, 2021
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trialChristopher P Fox, Ayesha S Ali, Graham McIlroy, et al.
The Lancet. Haematology|February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectChristopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Lancet (London, England)|November 16, 2024
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialJeremy S Abramson, Matthew Ku, Mark Hertzberg, et al.
The Lancet. Haematology|July 3, 2025
Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeGandhi Damaj, Ali Bazarbachi, Philipp Berning, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|April 2, 2020
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survivalNicolás Martinez-Calle, Edward Poynton, Alia Alchawaf, et al.
Blood Advances|November 15, 2023
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experienceRohan Shotton, Rachel Broadbent, Alia Alchawaf, et al.
Haematologica|December 1, 2020
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trialAndrew R Pettitt, Richard Jackson, Silvia Cicconi, et al.
Neuro-Oncology|February 9, 2021
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)Ramon F Barajas, Letterio S Politi, Nicoletta Anzalone, et al.
Blood Advances|August 31, 2021
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trialChristopher P Fox, Ayesha S Ali, Graham McIlroy, et al.
The Lancet. Haematology|February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectChristopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Lancet (London, England)|November 16, 2024
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trialJeremy S Abramson, Matthew Ku, Mark Hertzberg, et al.
The Lancet. Haematology|July 3, 2025
Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines CommitteeGandhi Damaj, Ali Bazarbachi, Philipp Berning, et al.
Pageof 13